Can an Alzheimer’s drug help prevent cerebral palsy?

A drug used to treat Alzheimer’s patients may reduce the brain damage that afflicts many premature infants, report researchers from Children’s Hospital Boston. Although the study involved a rat model of cerebral palsy and brain injury in premature infants, the findings may provide the basis for a protective therapy for preterm babies. No such therapy currently exists.

An increase in multiple gestations has led to more premature, very-low-birth weight infants. While more of these babies are surviving, up to 35 percent are left with brain injuries leading to cerebral palsy and cognitive/behavioural deficits. During the past decade, researchers at Children’s have documented a complex web of insults sustained by premature babies’ brain cells, particularly the cells that form the brain’s white matter, known as oligodendrocytes. Hypoxia-ischemia, a compromise of the brain’s blood and oxygen supply, is often the trigger. Not only are preemies at high risk for hypoxia-ischemia, but their immature oligodendrocytes are exquisitely vulnerable to hypoxic-ischemic injury because of the developing cells’ unique biology.

Now, in the June 25 issue of the Journal of Neuroscience, Frances Jensen, MD, Simon Manning, MD, Delia Talos, MD, and colleagues in Children’s Department of Neurology and Neurobiology Program demonstrate that the Alzheimer’s drug memantine can reduce white-matter injury after a hypoxic-ischemic episode. The drug, marketed in the U.S. as Namenda®, acts by blocking a type of glutamate receptor in the brain known as the NMDA receptor.

Jensen and colleagues first showed that the immature oligodendrocytes of preterm infants make NMDA receptors at the time in development when they are most vulnerable to white-matter injury, mirroring the pattern seen in rats. As a result, after a hypoxic-ischemic insult, the neurotransmitter glutamate accumulates in brain tissue and can cause over-activation of NMDA receptors, leading to a pattern of white-matter injury known as periventricular leukomalacia (PVL). But when rats were treated with memantine after a hypoxic-ischemic insult, this over-activation did not occur and white-matter injury was significantly reduced. The normal development of oligodendrocytes appeared to be unaffected.

"The premature brain is not just a ‘small’ adult brain — it is physiologically different and thus contains unique targets for therapy," says Jensen, the study’s senior investigator. "The NMDA receptor in white matter may be one of those targets. We tested this target in the animal model, and we also show that it is present in the premature human brain."

The next step is to evaluate potential safety risks of memantine in premature newborns. Eventually, Jensen and colleagues hope to conduct a clinical trial in premature infants at risk for PVL.

(Source: Journal of Neuroscience: Children’s Hospital Boston: July 2008)